Maplight Therapeutics (NASDAQ:MPLT) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of Maplight Therapeutics (NASDAQ:MPLT) in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $35.00 price objective on the stock.

MPLT has been the topic of a number of other research reports. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price target on the stock. Zacks Research upgraded Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.80.

Maplight Therapeutics Stock Performance

Shares of NASDAQ MPLT opened at $17.49 on Thursday. The company’s 50-day moving average is $17.89. Maplight Therapeutics has a 52-week low of $12.24 and a 52-week high of $21.55. The stock has a market cap of $793.57 million and a P/E ratio of -0.47.

Insider Transactions at Maplight Therapeutics

In related news, Director George Pavlov acquired 10,658 shares of the stock in a transaction dated Wednesday, February 18th. The shares were purchased at an average cost of $17.48 per share, with a total value of $186,301.84. Following the transaction, the director directly owned 10,658 shares in the company, valued at approximately $186,301.84. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Timothy John Garnett acquired 14,124 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were bought at an average price of $17.89 per share, with a total value of $252,678.36. Following the completion of the purchase, the director owned 14,124 shares in the company, valued at $252,678.36. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Hedge Funds Weigh In On Maplight Therapeutics

A number of hedge funds have recently modified their holdings of the company. Millennium Management LLC bought a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $245,000. Invesco Ltd. bought a new position in Maplight Therapeutics in the 4th quarter worth $228,000. Deutsche Bank AG purchased a new stake in Maplight Therapeutics in the 4th quarter worth $210,000. Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth $205,000. Finally, MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter valued at about $172,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.